facebook pixel

Research & Pipeline

A disease may be rare, but its treatment should not be

Catalyst is investing in the science of possibility—discovering, developing, and delivering innovative, life-changing medicines and solutions to transform patients’ lives and address their most important unmet medical needs. It’s all about the company you keep. At Catalyst, we are laser-focused on developing therapies for rare neuromuscular and neurological disorders—we believe this is where we can have the greatest impact on patients’ lives.

Catalyst received FDA-approval for its amifampridine product for Lambert-Eaton myasthenic syndrome (LEMS) in 2018 and has successfully commercialized the product.